Biogen Inc(BIIB-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low194.04
Day High201.75
Open:195.14
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Palvella Therapeutics (PVLA)
StockStory
3 Overrated Stocks Walking a Fine Line
BIIB
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Biogen Shareholders Back Board, Auditor and Pay Policies
StockStory
1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky
ORLY
Tipranks
Biogen Advances BIIB115 in Post–Gene Therapy SMA: Early Signals for Long‑Term Growth
Zacks Investment Research
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
BIIB's Next-Gen SMA Therapy Salanersen Wins FDA's Breakthrough Tag
Motley Fool
Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock.
GlobeNewswire
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
GlobeNewswire
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
Tipranks
Biogen and Denali’s BIIB122 Parkinson’s Trial Completion Sets Up Key Catalyst for Investors
Tipranks
Analysts Offer Insights on Healthcare Companies: Savara (SVRA) and Biogen (BIIB)
Tipranks
RBC Capital Reaffirms Their Buy Rating on Biogen (BIIB)
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Bicara Therapeutics Inc. (BCAX)
MarketBeat
MarketBeat Week in Review – 05/18 - 05/22
MarketBeat.com
MarketBeat
Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish
MarketBeat.com
GlobeNewswire
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
Tipranks
Biogen Earnings Call Signals Confident, Investment-Heavy Transition

Profile

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.